MedPharm moves into $4M expansion of its North Carolina facility5 Dec 2019
Expansion increases capacity for the company's topical and transdermal services, as well as dedicated innovation, microbiology and histology laboratories.
MedPharm, experts in topical and transdermal drug delivery, has moved into its newly expanded facility in Durham, North Carolina.
The $4-million expansion has tripled the facility’s footprint to approximately 25,000 sq. ft significantly expanding capacity and supporting MedPharm’s continued commitment to the topical and transdermal market.
Investment into the site was made following increased demand for MedPharm’s topical and transdermal services. The expansion covers pre-formulation and formulation development, in vitro release, in vitro penetration/permeation, tissue culture, analytical/bioanalysis, custom device development and tissue engineering. In addition, the new space will include dedicated innovation, microbiology and histology laboratories.
“We are excited to be able to offer an expanded and unmatched level of services from our facility in the North Carolina Research Triangle Park area”, commented Eugene Ciolfi MedPharm’s President and CEO. “The expanded space has a streamlined workflow that segregates phases of work and makes transition through each project more efficient with complimentary equipment positioned where it’s most needed.”
The new laboratory expands capacity for MedPharm’s proprietary models which de-risk its customers’ development programs as it accommodates automated and high throughput analytical instrumentation to improve turnaround times and elevate the consistent quality of data for clients.
The facility’s unique, dedicated innovation Lab will allow MedPharm to continue its pioneering approach to the development of custom performance testing models to meet unmet customer needs in the topical and transdermal markets. This investment also means that MedPharm can react quickly to solving project-specific problems for its customers and stay at the forefront of the latest scientific breakthroughs and technology.
The expansion will also create over 100 new highly skilled scientific and strategic positions in Research Triangle Park in North Carolina.
Pioneer in Phenylketonuria to begin clinical trial with gene therapy
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
Catalent launches direct-to-patient clinical supply services
14 Jan 2020
Multiple options provide increased flexibility for sponsors.Read more
Biogen to acquire novel clinical-stage asset from Pfizer
14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.Read more
French regulator agrees to partial resumption of Tellomak trial patient recruitment
14 Jan 2020
The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...Read more
Lupin could face FDA regulatory action over Tarapur API facility
13 Jan 2020
India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.Read more
Partnership formed to develop and commercialise ready-to-use medicine
13 Jan 2020
The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.Read more
ReadCoor to commercially launch spatial sequencing platform
10 Jan 2020
Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.Read more
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API
9 Jan 2020
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation